What is Archimedes?
ArchimedesRx operates as a sophisticated specialty drug management platform designed to address the escalating costs associated with complex medication therapies. By serving employers and health plans, the company provides a robust alternative to legacy pharmacy benefit manager (PBM) structures. Its core value proposition lies in the alignment of financial incentives with clinical outcomes, utilizing advanced data analytics to identify cost-saving opportunities without compromising patient care. Through its value-based coverage framework, Archimedes enables stakeholders to navigate the specialty drug landscape with greater predictability and fiscal control, effectively managing expenditures while ensuring that patients receive necessary clinical oversight.
How much funding has Archimedes raised?
Archimedes has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Archimedes
PPP
Public-Private Partnership
What's next for Archimedes?
With this late-stage funding, Archimedes is well-positioned to scale its operations and further penetrate the health plan market. The strategic roadmap likely involves enhancing its proprietary technology stack to deepen its analytical capabilities regarding specialty drug utilization. As the healthcare industry continues to shift toward value-based care, Archimedes is poised to capture additional market share by offering a transparent, data-driven solution that directly challenges the opaque pricing models of incumbent PBMs. Future growth will likely focus on expanding its client base among large-scale employers seeking to mitigate the financial burden of specialty medications while maintaining high standards of clinical efficacy.
See full Archimedes company page
